Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MKC-1: Interim Phase II data

Interim Phase II data from 35 evaluable metastatic breast cancer patients

Read the full 118 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE